Daiichi Sankyo Company, Limited

The University of Tokyo

Osamu Kanno

Jun Watanabe

Yoshito Hamada

Daisuke Honma

Nobuaki Adachi

Keisuke Suzuki

Kazumasa Aoki

Katsuyoshi Nakajima

Akira Nakao

Takao Horiuchi

Shimpei Hirano

Ryoichi Tanaka

Tomonori Yamasaki

Kiyoshi Oizumi

Makoto Yamagishi

Toshiki Watanabe

Satoru Naito

Daigo Asano

The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1, 3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R, R, R, R, R, R, and V in the formula (I) are each as defined in the present specification). 

1,3-benzodioxole derivative

The present invention provides an agent for treating and/or preventing adult T cell leukemia/lymphoma containing a compound having a specific chemical structure or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides an agent for treating and/or preventing adult T cell leukemia/lymphoma containing, as an active ingredient, 7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide or a pharmaceutically acceptable salt thereof, or 7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide or a pharmaceutically acceptable salt thereof.

Agent for treating and/or preventing adult T cell leukemia/lymphoma

The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1,3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R, R, R, R, R, R, and V in the formula (I) are each as defined in the present specification). 

Compounds exhibiting an osteogenesis-promoting action having the general formula (I) or a pharmacologically acceptable salt thereof: 

Cyclic compound having hetero atom

Low molecular weight compound exhibiting an osteogenesis-promoting action having the general formula (I) or a pharmacologically acceptable salt thereof: 

Cyclic compound having substituted phenyl group

Growing community of inventors

Tokyo, Japan

Osamu Kanno